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Originating Technology/NASA Contribution
Langley Research Center’s Soluble Imide (LaRC-SI) was discovered by accident. While researching resins and adhesives for advanced composites for 
high-speed aircraft, Robert Bryant, a Langley engineer, 
noticed that one of the polymers he was working with 
did not behave as predicted. After putting the compound 
through a two-stage controlled chemical reaction, expect-
ing it to precipitate as a powder after the second stage, he 
was surprised to see that the compound remained soluble. 
This novel characteristic ended up making this polymer 
a very significant finding, eventually leading Bryant and 
his team to win several NASA technology awards, and an 
“R&D 100” award. 
The unique feature of this compound is the way that it 
lends itself to easy processing. Most polyimides (members 
of a group of remarkably strong and incredibly heat- and 
chemical-resistant polymers) require complex curing 
cycles before they are usable. LaRC-SI remains soluble 
in its final form, so no further chemical processing is 
required to produce final materials, like thin films and 
varnishes. Since producing LaRC-SI does not require 
complex manufacturing techniques, it has been processed 
into useful forms for a variety of applications, includ-
ing mechanical parts, magnetic components, ceramics, 
adhesives, composites, flexible circuits, multilayer printed 
circuits, and coatings on fiber optics, wires, and metals.
Bryant’s team was, at the time, heavily involved 
with the aircraft polymer project and could not afford 
to further develop the polymer resin. Believing it was 
worth further exploration, though, he developed a plan 
for funding development and submitted it to Langley’s 
chief scientist, who endorsed the experimentation. Bryant 
then left the high-speed civil transport project to develop 
LaRC-SI. The result is an extremely tough, lightweight 
thermoplastic that is not only solvent-resistant, but also 
has the ability to withstand temperature ranges from 
cryogenic levels to above 200 °C. The thermoplastic’s 
unique characteristics lend it to many commercial 
applications; uses that Bryant believed would ultimately 
benefit industry and the Nation. “LaRC-SI,” he explains, 
“is a product created in a government laboratory, funded 
with money from the tax-paying public. What we 
discovered helps further the economic competitiveness 
of the United States, and it was our goal to initiate the 
technology transfer process to ensure that our work 
benefited the widest range of people.”  
Several NASA centers, including Langley, have 
explored methods for using LaRC-SI in a number of 
applications from radiation shielding and as an adhesive 
to uses involving replacement of conventional rigid circuit 
boards. In the commercial realm, LaRC-SI can now be 
found in several commercial products, including the thin-
layer composite unimorph ferroelectric driver and sensor 
(THUNDER) piezoelectric actuator, another “R&D 
100” award winner (Spinoff 2005). 
Partnership
Working with the Innovative Partnerships Program 
office at Langley, Medtronic Inc., of Minneapolis, 
Minnesota, licensed the material. This material has 
been evaluated for space applications, high-performance 
composites, and harsh environments; however, this part-
nership represents the first time that the material has been 
used in a medical device. 
According to Bryant, “This partnership validates the 
belief we had that LaRC-SI needed to be introduced in 
(or by) the private sector: Lives can be saved and enhanced 
Medtronic’s cardiac resynchronization therapy devices use the NASA-developed polymer as insulation on thin metal lead wires.
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because we were able to develop our laboratory findings 
and provide public access to the material.”
Product Outcome
Medtronic is the world leader in medical technology 
providing lifelong solutions for people with chronic 
disease. It offers products, therapies, and services that 
enhance or extend the lives of millions of people. Each 
year, 6 million patients benefit from Medtronic’s tech-
nology, used to treat conditions such as diabetes, heart 
disease, neurological disorders, and vascular illnesses.
The company is testing the material for use as insu-
lation on thin metal wires connected to its implantable 
cardiac resynchronization therapy (CRT) devices for 
patients experiencing heart failure, which resynchronize 
the contractions of the heart’s ventricles by sending tiny 
electrical impulses to the heart muscle, helping the heart 
pump blood throughout the body more efficiently. 
 “Our work with NASA Langley was very collab-
orative,” said Lonny Stormo, Medtronic vice president 
of therapy delivery research and development. “Our 
scientists discussed Medtronic’s material requirements 
and NASA shared what it knows about the compound’s 
properties as we continued our testing and evaluations.”
In March 2007, Medtronic conducted the first 
clinical implants in the United States and Canada of 
the Medtronic over-the-wire lead (Model 4196), a dual-
electrode left ventricular (LV) lead for use in heart failure 
patients with cardiac resynchronization therapy devices. 
 “Through this partnership, Medtronic was able to 
deliver a product with enhanced material properties,” said 
Stormo. “In turn this helps our patients, which is the core 
of Medtronic’s mission.” 
Placing a lead in the LV is widely recognized by 
physicians as the most challenging aspect of implanting 
CRT devices. Anatomic challenges can make it difficult 
to access and work within the coronary sinus to place a 
lead in the desired vein of the LV. The lead is specially 
designed for optimal tracking over a guide wire, which is 
intended to allow physicians greater ability to deliver the 
left heart lead in difficult-to-access veins. 
Once implanted in the LV, two electrodes located at 
the tip of the lead provide physicians with options to tailor 
delivery of stimulation for each patient. When approved 
by the U.S. Food and Drug Administration, the lead is 
expected to be the smallest LV lead in the U.S. market. v
LaRC-SI is an amorphous thermoplastic developed by Robert 
Bryant, a chemical engineer at Langley. LaRC-SI has excellent 
adhesive and dielectric properties and can be reformed at 
elevated temperature and pressures. It can be applied in the 
form of a spray, spin, dip coating, paint, or spread with a blade.
